The aim is to see whether the new version of the medicine helps people lose weight at least as well as the existing version and better than the placebo. Participants receive an injection once a week for about six months, and their body weight is measured at the start and at the end of the treatment period.

During the study, researchers watch for any adverse events (side effects) and especially for serious adverse events (more serious health problems). After the six‑month treatment phase, participants are followed for a few more weeks to complete safety monitoring.

The purpose of the study is to evaluate the safety and how the drug behaves in the body. Participants receive a single dose of either the study drug or the comparison solution, followed by several additional doses over a number of weeks. During this time, regular check‑ups, blood tests, and heart rhythm recordings (electrocardiogram) are performed to watch for side effects and to measure drug levels. The trial also examines whether the treatment changes the amount of a protein called C‑peptide, which reflects the pancreas’s remaining ability to produce insulin.

The purpose of this study is to determine if daily oral orforglipron is as effective as insulin glargine (an injectable insulin) in preventing major heart-related events in these patients. The study will look at outcomes such as myocardial infarction (heart attack), stroke, hospitalization for unstable angina (chest pain), and death related to heart disease.

This is a Phase 3, open-label study, which means participants and researchers will know which treatment is being given. Participants will either take orforglipron once daily by mouth or use insulin glargine injections while continuing their existing diabetes medications. The study will monitor their health status over time to compare the safety and effectiveness of these two treatment approaches.

The purpose of the study is to determine how safe and well‑tolerated the medication is for people with this disorder. Participants will be randomly assigned to receive either the active drug or a placebo in a double-blind manner (meaning neither the participants nor the study staff know which treatment is being given) and will be followed for several weeks with regular check‑ups, blood tests, and heart rhythm recordings. Researchers will also look at whether the body creates an immune response to the drug, known as immunogenicity (the tendency to trigger antibodies).

During the study, volunteers will attend clinic visits where they will receive the assigned injection, have blood drawn to measure drug levels and metabolic markers, and undergo simple safety assessments such as blood pressure checks and an electrocardiogram (a test that records the heart’s electrical activity). Any side effects or changes in laboratory results will be recorded, and the overall health and quality‑of‑life information will be collected throughout the treatment period.

The main aim is to learn how the medicine is taken up into the blood when it is injected in different places on the body. Researchers will compare injections given in the thigh, the upper arm, and the abdomen to see which site allows the best bioavailability. Two key measurements are used: AUCinf, which reflects the total amount of drug that reaches the bloodstream over time, and Cmax, which shows the highest level of drug in the blood after the injection.

Participants will receive one injection and then stay for a short monitoring period. During this time blood samples are taken, vital signs such as blood pressure are checked, and a heart test called an ECG is performed. Safety is also assessed with two questionnaires: the C-SSRS, which looks for thoughts of self‑harm, and the PHQ-8, which screens for symptoms of depression.

Table of contents

• Trial overview
• Who is being studied
• What is being tested
• Study phase and design
• What outcomes are measured
• How to read the study results

Trial overview

The available trial for TRIACYLGLYCEROL LIPASE is a Phase 2 interventional study in adults with exocrine pancreatic insufficiency (EPI).^[1] It is authorised and plans to enroll 44 participants.^[1]

The study title says it will evaluate safety and explore efficacy of a new lipase called NHS7108 compared with pancrelipase.^[1] “Efficacy” means how well a treatment works.^[1]

Who is being studied

This trial is for adult participants with exocrine pancreatic insufficiency.^[1] EPI is the condition being studied, and the trial data do not give more detailed eligibility rules.^[1]

People in this study are being followed because they need support with digestion and nutrient absorption.^[1] The study is not described as a pediatric trial, so the listed population is adults only.^[1]

What is being tested

The study compares NHS7108 capsules with Zenpep delayed-release capsules, which are listed as pancrelipase in the trial record.^[1] Both are given by mouth.^[1]

The brief summary says different doses of NHS7108 are given daily for 14 days in participants with EPI.^[1] This means the researchers are looking at short-term treatment effects over two weeks.^[1]

Study phase and design

This is an interventional trial, which means participants receive a study treatment and researchers observe the effects.^[1] It is a Phase 2 study, so the main focus is safety with early signs of benefit.^[1]

Phase 2 studies often help researchers decide whether a treatment should be studied further in larger groups.^[1] In this trial, the study is also meant to compare the new treatment with an existing one used for the same condition.^[1]

What outcomes are measured

The main safety outcome is the number of participants who report one or more adverse events.^[1] An adverse event is any unwanted health problem that happens during the study.^[1]

Researchers also track changes from baseline in safety parameters after 14 days of NHS7108 treatment.^[1] These safety checks include clinical laboratory tests, vital signs, 12-lead electrocardiogram (ECG), and physical examination.^[1]

Another key measure is the change from baseline in coefficient of nitrogen absorption (CNA) after 14 days.^[1] CNA is used here as a way to assess how well the body absorbs nitrogen, which helps show protein absorption.^[1]

How to read the study results

Because this is a small Phase 2 study, the results will mainly help show whether the treatment is safe enough and whether it may be worth studying more.^[1] The study does not yet provide final proof that the treatment works better than the comparison treatment.^[1]

For patients, the most important points are the condition studied, the adult population, the short 14-day treatment period, and the safety-focused outcomes.^[1] These details show that the trial is an early step in learning more about TRIACYLGLYCEROL LIPASE-related treatment research.^[1]

Table of contents

• Overview of the trials
• Who the trials are for
• Trial phases and study design
• Main endpoints and what they mean
• Trial summary

Overview of the trials

These clinical trials are studying KAI-9531 in people living with obesity, and in one study, people with obesity or overweight and diabetes.^[1][2][3]

The studies are designed to look at efficacy (how well a treatment works) and safety (how well it is tolerated), using comparisons with semaglutide or placebo.^[1][2][3]

Who the trials are for

One trial is for participants living with obesity who do not have diabetes.^[1]

Another trial is for participants living with obesity or overweight and diabetes.^[2]

The third trial is for participants living with obesity or overweight with weight-related comorbidities and who do not have diabetes.^[3]

A comorbidity is another health problem that happens along with the main condition.^[3]

Trial phases and study design

All three studies are Phase 3 trials, which means they are late-stage studies in larger groups of people.^[1][2][3]

Each study is interventional, meaning researchers assign a treatment and then measure the results.^[1][2][3]

In one trial, KAI-9531 is compared with semaglutide and placebo.^[1]

In the other two trials, KAI-9531 is compared with placebo.^[2][3]

Main endpoints and what they mean

The main outcome in two studies is percent change in body weight from the start of the trial to Week 76.^[1][3]

The study in participants with diabetes also measures change in hemoglobin A1c at Week 76.^[2]

Hemoglobin A1c is a blood test that shows average blood sugar over time, so it helps researchers see whether blood sugar control changes during the study.^[2]

The trial comparing KAI-9531 with semaglutide is designed to show that KAI-9531 is better than semaglutide and placebo for percent change in body weight.^[1]

The study in people with diabetes is designed to show that KAI-9531 is better than placebo for both body weight change and HbA1c change.^[2]

Trial summary

Table of Contents

• Trial overview
• Who is being studied
• Study phase and design
• What researchers measure
• Trial status and size

Trial overview

The available trial is a first-in-human study of ADENO-ASSOCIATED VIRUS SEROTYPE 9 CONTAINING THE HUMAN GCG GENE in adults with inadequately controlled type 2 diabetes.^[1] It is designed to evaluate safety and tolerability, which means the researchers want to see how the study treatment is handled by the body and whether it causes important problems.^[1]

Who is being studied

The target population is adults with type 2 diabetes whose condition is not well controlled.^[1] The source data does not give more details about age limits, lab cutoffs, or other eligibility rules, so only this group can be confirmed from the trial record.^[1]

Study phase and design

This study is listed as a Phase 1/2 trial.^[1] Early-phase trials like this usually focus first on safety, and they may also begin to look for early signs that the treatment has a useful effect.^[1]

The trial is interventional, which means participants receive the study treatment rather than only being observed.^[1] The intervention is listed as RJVA-001 given by endoscopic ultrasound-guided delivery, a procedure that uses an endoscope and ultrasound imaging to guide treatment placement inside the body.^[1]

What researchers measure

The main outcome is the incidence and severity of adverse events, plus any dose-relationship and changes in laboratory evaluations.^[1] Adverse events are unwanted medical problems that happen during a study, and laboratory evaluations are tests such as blood work that help researchers watch for changes in health.^[1]

These outcomes are important because they help show whether the treatment appears safe enough for further study and whether different treatment amounts may affect the body differently.^[1]

Trial status and size

The trial status is Authorised, which means it has been approved to begin according to the source record.^[1] The planned enrollment is 50 participants, making this a small early study.^[1]

Table of contents

• Trial overview
• Who is being studied
• Trial goals and endpoints
• Trial phases and status
• Study design and comparators
• Key trials
• Patient-focused terms

Trial overview

The clinical trials in this article study LY3841136 SODIUM, which is also named eloralintide in the trial titles.^{[1][2][3][4][5]}

All five listed studies are interventional trials, which means participants are assigned to receive a study treatment or a comparison treatment.^{[1][2][3][4][5]}

The main research focus is body weight change in people with obesity or overweight, with some studies also looking at sleep apnea or knee pain from osteoarthritis.^{[1][2][3][4][5]}

Who is being studied

The trials include people with obesity or overweight, which are the main target populations across the studies.^{[1][2][3][4][5]}

One study includes participants with obstructive sleep apnea and obesity or overweight.^[1]

One study includes participants with obesity or overweight and type 2 diabetes.^[4]

One study includes participants with osteoarthritis knee pain and obesity or overweight.^[3]

One study includes participants with persistent obesity who are treated with a weekly incretin, which is the wording used in the trial title.^[5]

Trial goals and endpoints

The main goal in most studies is to show that LY3841136 SODIUM is better than placebo for percent change from baseline in body weight.^[1][2][4][5]

In the study of obstructive sleep apnea, the trial also aims to show superiority over placebo for apnea-hypopnea index, which is a measure of how often breathing stops or becomes shallow during sleep.^[1]

In the osteoarthritis study, the two main goals are body weight change and change in the WOMAC pain subscale score, which measures knee pain from osteoarthritis.^[3]

Several studies measure body weight change at Week 64, showing that the trials are designed to follow results over a long period.^[2][4][5]

Trial phases and status

All listed studies are in Phase 3, the stage where a treatment is tested in larger groups of people to confirm how well it works.^{[1][2][3][4][5]}

Each trial is marked Authorised, which means the studies have been approved to move forward in the source data.^{[1][2][3][4][5]}

The study sizes are fairly large, with enrollment ranging from 254 to 1035 participants.^{[1][2][3][4][5]}

Study design and comparators

These studies compare LY3841136 SODIUM with a placebo, which is a look-alike treatment used to make the comparison fair.^{[1][2][3][4][5]}

The trial titles show that LY3841136 SODIUM is given by subcutaneous use, meaning it is given under the skin.^{[1][2][3][4][5]}

The source data do not provide detailed eligibility rules, so the safest summary is that these studies are for adults with the conditions named in each trial title.^{[1][2][3][4][5]}

Key trials

ENLIGHTEN-1 studies participants with obesity or overweight without type 2 diabetes and measures percent change from baseline in body weight at Week 64.^[2]

ENLIGHTEN-2 studies participants with obesity or overweight and type 2 diabetes, also with body weight change as the main outcome.^[4]

ENLIGHTEN-3 studies participants with obstructive sleep apnea and obesity or overweight, and it looks at both body weight and apnea-hypopnea index.^[1]

ENLIGHTEN-4 studies participants with osteoarthritis knee pain and obesity or overweight, and it measures body weight plus WOMAC pain score.^[3]

ENLIGHTEN-6 studies participants with persistent obesity who are treated with a weekly incretin, and it focuses on body weight change.^[5]

Patient-focused terms

Baseline means the starting point before treatment begins.^[2][3][4][5]

Percent change from baseline means how much a value changes compared with the starting value, shown as a percent.^{[1][2][3][4][5]}

Primary outcome means the main result the researchers want to measure in the trial.^{[1][2][3][4][5]}

Enrollment means the number of participants planned for the study.^{[1][2][3][4][5]}

Table of contents

• Trial overview
• Condition and population studied
• Treatments being tested
• Trial phase and design
• What the trial measures
• What this means for patients

Trial overview

This clinical trial studied ZALFERMIN in people with alcohol-related liver disease, a liver condition linked to alcohol use.^[1] The study was interventional, which means researchers assigned treatments and then compared outcomes.^[1] It was a Phase 2 trial and was marked as completed.^[1]

Condition and population studied

The trial focused on adults with alcohol-related liver disease.^[1] The study data do not give more detailed entry rules, so the exact participation criteria are not fully listed here.^[1] In simple terms, the study looked at people who already had liver problems related to alcohol use.^[1]

Treatments being tested

The trial compared ZALFERMIN with other study treatments and with placebo, which is an inactive treatment used for comparison.^[1] The listed interventions included cagrilintide, semaglutide, combinations of these drugs, placebo, and ZALFERMIN given by subcutaneous injection, meaning under the skin.^[1] The study summary says the goal was to test these treatment options alone and in combination versus placebo for liver damage and function.^[1]

Trial phase and design

This was a Phase 2 study, which is a mid-stage trial that looks more closely at whether a treatment may work and keeps checking safety.^[1] The study type was interventional, so the research team actively assigned the study treatments instead of only observing people.^[1] The enrollment was 287 people, showing a moderate-size trial group for this type of research.^[1]

What the trial measures

The main outcome was the change in Enhanced Liver Fibrosis (ELF).^[1] ELF is a blood test-based measure used to help estimate liver fibrosis, which means scarring in the liver.^[1] By tracking this change, the study aimed to see whether the treatments could improve or affect liver damage and liver function.^[1]

What this means for patients

For patients, this trial shows that ZALFERMIN is being explored as part of research for alcohol-related liver disease, not as a routine treatment described in this data.^[1] The study looked at whether ZALFERMIN and related treatment combinations could help with liver injury compared with placebo.^[1] Because the trial is completed, the next step would be to review the results to understand whether the treatment approach was helpful.^[1]

Table of Contents

• Trial overview
• Study design and treatments
• Who can participate
• What is being measured
• What the results may mean for patients
• Key terms explained

Trial overview

The clinical trial for ZINC is studying zinc acetate dose regimens in relation to Wilson’s disease.^[1] It is an interventional study, which means researchers assign the treatments and then measure the effects.^[1]

This study is listed as Phase 2 and is authorised.^[1] The planned enrollment is 36 participants.^[1]

Study design and treatments

The study compares three treatment groups: Galzin 50 mg three times daily, ET-700 75 mg twice daily, and placebo.^[1] The trial summary says the goal is to see how these regimens affect intestinal copper absorption in healthy volunteers.^[1]

The trial also uses 64Cu PET/CT, a scan method that helps researchers track a copper tracer in the body.^[1] In this study, the amount of tracer found in the liver is used as a sign of copper absorption.^[1]

Who can participate

The available data say that the study is being done in healthy participants.^[1] No other inclusion or exclusion details are provided in the trial record.^[1]

This is important because the study is not testing people with Wilson’s disease directly in the provided record.^[1] Instead, it is designed to help researchers understand copper absorption under controlled study conditions.^[1]

What is being measured

The main endpoint is the change in mean hepatic 64Cu standard uptake value (SUV) from before to after the intervention between the three groups.^[1] SUV is a number that shows how much of the tracer is taken up by an organ, here the liver.^[1]

Because the liver is a major organ for copper handling, this measurement helps researchers compare how the different regimens affect copper movement in the body.^[1] The study summary specifically says the scans are being used to assess intestinal copper absorption by measuring the amount of 64Cu in the liver.^[1]

What the results may mean for patients

For patients, this trial is mainly about learning whether different zinc acetate schedules change copper absorption in a measurable way.^[1] That information may help build better research knowledge for Wilson’s disease.^[1]

The trial does not provide final results in the source data, so it cannot yet show which regimen works best.^[1] It does show that researchers are comparing active treatment with placebo and using imaging to measure the effect.^[1]

Key terms explained

Wilson’s disease is the condition named in the trial record and is linked to copper handling in the body.^[1] Placebo means a look-alike treatment with no active study drug, used for comparison.^[1]

Interventional means the researchers give the treatments rather than only observing what happens.^[1] Authorised means the study has been approved to start according to the record provided.^[1]

Healthy volunteers are people without the disease being studied, and they help researchers make clearer comparisons.^[1] Endpoint means the main result the study is designed to measure.^[1]

Table of contents

• Trial overview
• Who was studied
• What the study measured
• Trial phase and status
• Key patient terms

Trial overview

The clinical trial NCT06072326 was an interventional study, which means researchers planned to assign treatments and then measure what happened.^[1] It studied N-[5-(2H-1,3-BENZODIOXOL-5-YL)-6-{2-[(5-BROMOPYRIMIDIN-2-YL)OXY]ETHOXY}PYRIMIDIN-4-YL]-N’-(2-METHOXYETHYL)SULFURIC DIAMIDE in adults with chronic kidney disease and type 1 diabetes.^[1]

The brief summary says the study aimed to compare dapagliflozin plus the study drug versus the study drug alone for albuminuria, which means too much albumin in the urine.^[1]

Who was studied

The target population was adults with type 1 diabetes and chronic kidney disease who had elevated urinary albumin excretion.^[1] This means the study focused on people whose kidneys were already affected and who were losing extra albumin in the urine.^[1]

The trial planned to enroll 36 participants.^[1] That small number is common in early-stage studies that look closely at whether a treatment may help in a specific group.^[1]

What the study measured

The main endpoint was the change from baseline in urine albumin-creatinine ratio (UACR).^[1] Baseline means the starting measurement before treatment begins.^[1] UACR is a urine test that helps show how much albumin is leaking into the urine, so it is often used to track kidney-related changes.^[1]

The primary comparison was SC0062 alone versus the combination of dapagliflozin and SC0062.^[1] The source data do not list other outcomes, so the main focus described here is the UACR result.^[1]

Trial phase and status

This study was in Phase 2.^[1] Phase 2 trials usually look more closely at whether a treatment may work in a defined patient group while continuing safety checks.^[1]

The trial status was Withdrawn.^[1] In practical terms, this means the study did not go ahead as planned and the source data do not provide trial results.^[1]

Key patient terms

Albuminuria means too much albumin is present in the urine, which can be a sign of kidney damage.^[1] Combination treatment means two treatments are used together in the same study.^[1]

Elevated urinary albumin excretion means the body is passing more albumin into the urine than normal.^[1] In this trial, that feature helped define who could be studied.^[1]

Table of Contents

• Trial overview
• Who is being studied
• Study design and treatment groups
• What is being measured
• Trial status and size

Trial overview

The listed study of SONLICROMANOL HYDROCHLORIDE is a randomized, double-blind, placebo-controlled Phase 2 trial in people with long COVID.^[1] It is an interventional study, which means the researchers assign a treatment and then measure the results.^[1]

The trial is authorised and plans to enroll 80 participants.^[1] Its brief summary says the study is looking at reduction of post-COVID related fatigue measured with the FAS at week 13.^[1]

Who is being studied

The target condition is long COVID, also called post-COVID symptoms in the study summary.^[1] The main symptom being studied is fatigue, which means ongoing tiredness or low energy.^[1]

This means the trial is focused on people whose symptoms continue after a COVID-19 infection, especially those affected by persistent fatigue.^[1]

Study design and treatment groups

The trial is randomized, so participants are assigned to study groups by chance.^[1] It is also double-blind, which means neither the participants nor the study team know who receives the active treatment or the placebo during the study.^[1]

The comparison is between SONLICROMANOL HYDROCHLORIDE and placebo, an inactive look-alike treatment used to help show whether the study drug has a real effect.^[1] The intervention list includes Sonlicromanol tablets and a placebo, and also lists Sonlicromanol 180 mg by buccal use.^[1]

What is being measured

The primary outcome is fatigue symptoms measured at week 13 by the FAS.^[1] A primary outcome is the main result the researchers want to study.^[1]

The FAS is a fatigue assessment scale, which is a tool used to measure how severe tiredness is.^[1] In simple terms, the study wants to see whether SONLICROMANOL HYDROCHLORIDE can improve fatigue more than placebo after 13 weeks.^[1]

Trial status and size

The study status is Authorised, which means it has approval to proceed.^[1] With 80 planned participants, this is a small Phase 2 study designed to give an early answer about possible benefit in long COVID fatigue.^[1]

Because the trial is still in Phase 2, the main goal is to learn more about whether the treatment may help and to continue evaluating it in a limited group of patients.^[1]

Table of Contents

• Trial overview
• Who is being studied
• Study design and phase
• What researchers are measuring
• Treatment regimens in the study
• Why this trial matters

Trial overview

The main trial in the data is the SAFEGUARD study, which stands for SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes. It is studying HUMAN POLYCLONAL IMMUNOGLOBULIN G AGAINST THYMOCYTE in people with type 1 diabetes.^[1]

The study is authorised, which means it has been approved to move forward in the listed setting.^[1]

Who is being studied

This trial is for people who were recently diagnosed with stage 3 type 1 diabetes.^[1]

Stage 3 type 1 diabetes means the disease is already clearly present and diagnosed, and the study focuses on this early period after diagnosis.^[1]

Study design and phase

This is an interventional study, which means the researchers are giving a study treatment and then watching what happens.^[1]

The trial is in Phase 2, a stage where researchers look more closely at safety and begin to test whether the treatment may help the disease.^[1]

The planned enrollment is 190 people.^[1]

What researchers are measuring

The primary outcomes include recording and reviewing any health problems or side effects that happen during the study.^[1]

Researchers are also checking measures of pancreas function related to insulin production, which helps show whether the pancreas is still making insulin well.^[1]

The brief summary says the study wants to learn about safety and tolerability, and also find out whether the treatment can slow the decline of insulin-producing cells in the pancreas over the course of the study.^[1]

Treatment regimens in the study

The intervention list includes SAB-142 given by intravenous administration and a sodium chloride infusion used as the comparison treatment.^[1]

SAB-142 is named in the trial details as the study drug linked to HUMAN POLYCLONAL IMMUNOGLOBULIN G AGAINST THYMOCYTE.^[1]

Why this trial matters

This study is trying to answer an important question: can treatment given soon after diagnosis help protect the pancreas in type 1 diabetes?^[1]

By focusing on safety, tolerability, and pancreas function, the trial is designed to show both how people handle the treatment and whether it may help preserve insulin-making cells.^[1]

Table of contents

• Trial overview
• Who is being studied
• What the trials measure
• Trial phases and status
• Trial designs and treatment plans
• Key patient terms

Trial overview

Two interventional studies are investigating ALFA-D-MANNOSE 1-PHOSPHATE DIPOTASSIUM through the study drug GLM101 in people with PMM2-CDG.^[1][2] Both studies are Phase 2 and are listed as authorised.^[1][2]

One study is focused on weekly doses and compares GLM101 with placebo to see whether symptoms of ataxia change after 24 weeks.^[1] The other is a long-term study that follows patients who previously received GLM101 to learn more about safety over time.^[2]

Who is being studied

The target condition in both trials is PMM2-CDG, which is the only condition named in the source data.^[1][2] The long-term study includes patients who already received GLM101 before joining this follow-up study.^[2]

The first trial plans to enroll 50 participants, and the long-term study plans to enroll 80 participants.^[1][2] This means the research is being done in relatively small groups, which is common in early testing stages.^[1][2]

What the trials measure

The main outcome in the weekly-dose study is the change from baseline in ICARS at 24 weeks.^[1] Baseline means the starting point before treatment begins, and ICARS is a score used to measure ataxia, which means problems with balance and coordination.^[1]

The long-term study mainly collects safety information.^[2] This includes side effects, deaths, stopping the study because of side effects, blood and urine tests, ECG results, vital signs, and changes in the physical exam compared with before treatment.^[2]

Trial phases and status

Both trials are in Phase 2, which usually means the treatment is being studied in a smaller group of patients to learn more about safety and possible benefit.^[1][2] Both studies are marked as authorised in the source data.^[1][2]

The first trial is designed to compare GLM101 with placebo, while the second trial follows patients over a longer period with GLM101 exposure already in their history.^[1][2] These two designs help researchers look at both short-term effect and longer-term safety.^[1][2]

Trial designs and treatment plans

In the first study, participants receive weekly doses of GLM101 or placebo by intravenous administration, which means the treatment is given into a vein.^[1] The source data lists the dose as 30 mg/kg for both GLM101 and the placebo infusion description.^[1]

In the long-term study, GLM101 is also given by intravenous use.^[2] The study is not focused on a new comparison with placebo; instead, it is built to watch what happens over time in patients who have already received the treatment.^[2]

Key patient terms

Ataxia means trouble with balance and coordination, which can affect walking and movement.^[1]

Placebo means a look-alike treatment used for comparison in a study, so researchers can see whether the study drug has a real effect.^[1]

Vital signs are basic health checks such as blood pressure, heart rate, and body temperature.^[2]

ECG is a heart tracing test that shows the heart’s electrical activity.^[2]

Urinalysis and blood tests help researchers watch for changes in body function during the study.^[2]

Table of Contents

• What is BI 764198?
• Target Condition: Focal Segmental Glomerulosclerosis (FSGS)
• Clinical Trial Details
• How BI 764198 Works
• Potential Benefits
• Eligibility Criteria
• Administration and Dosage
• Safety Considerations

What is BI 764198?

BI 764198 is a new experimental medication being developed to treat a specific kidney disease called focal segmental glomerulosclerosis (FSGS). Its chemical name is [4-(6-aminopyridazin-3-yl)piperidin-1-yl][5-(4-fluorophenoxy)-4-methoxypyridin-2-yl]methanone.^[1] This medication is currently undergoing clinical trials to assess its effectiveness and safety in patients with FSGS.

Target Condition: Focal Segmental Glomerulosclerosis (FSGS)

Focal segmental glomerulosclerosis (FSGS) is a serious kidney disease that affects the glomeruli, which are tiny filtering units in the kidneys. In FSGS, scar tissue develops in parts of the glomeruli, impairing their ability to filter blood properly. This leads to a condition called proteinuria, where excessive amounts of protein leak into the urine.^[1]

Clinical Trial Details

A clinical trial is currently underway to evaluate BI 764198. This trial is described as a “multicenter, randomized, double-blind, parallel group, placebo-controlled study.” Here are some key details about the trial:^[1]

• Duration: 12 weeks
• Main objective: To explore the efficacy of BI 764198 in reducing proteinuria (excess protein in urine)
• Secondary objectives: To investigate the pharmacokinetic profile of BI 764198 (how the drug moves through the body)

How BI 764198 Works

While the exact mechanism of action is not fully described in the trial information, BI 764198 is likely designed to target the underlying causes of FSGS or to help reduce proteinuria. The medication is being tested to see if it can effectively lower the amount of protein in the urine of patients with FSGS.^[1]

Potential Benefits

The main potential benefit being investigated is the reduction of proteinuria. The primary endpoint of the study is to determine the number of patients who achieve at least a 25% reduction in their urine protein-creatinine ratio (UPCR) after 12 weeks of treatment. This could potentially indicate an improvement in kidney function and a slowing of disease progression.^[1]

Eligibility Criteria

The trial has specific criteria for who can participate. Some key inclusion criteria are:^[1]

• Adults aged 18 to 75 years
• Diagnosed with biopsy-proven primary FSGS or documented TRPC6 gene mutation causing FSGS
• High levels of protein in the urine (UPCR ≥ 1000 mg/g)
• Stable doses of certain medications (if applicable), such as corticosteroids, ACE inhibitors, or ARBs

There are also several exclusion criteria, including certain other kidney conditions, uncontrolled high blood pressure, and use of specific medications.

Administration and Dosage

BI 764198 is administered as an oral capsule. The exact dosage is not specified in the trial information, but it is designed to be taken once daily for the 12-week study period.^[1]

Safety Considerations

As with any new medication, safety is a crucial aspect being studied in this trial. The researchers will be monitoring for any side effects or adverse reactions throughout the study period. It’s important to note that as an experimental drug, not all potential risks are known at this stage.^[1]

Patients considering participation in this or any clinical trial should discuss the potential risks and benefits thoroughly with their healthcare provider.

Table of contents

• Trial overview
• Who is being studied
• What the trial is measuring
• Trial design and phase
• Why this trial matters for patients

Trial overview

The source data describe one interventional study of ZIMISLECEL, identified as NCT04786262, with the status Authorised.^[1] The study title says it is a Phase 1/2/3 study to evaluate safety, tolerability, and efficacy in subjects with type 1 diabetes mellitus with impaired hypoglycemic awareness and severe hypoglycemia.^[1] The brief summary says the study is designed to evaluate the efficacy of VX-880 infusion in subjects with type 1 diabetes and impaired hypoglycemic awareness, which is the same patient group described in the title and condition field.^[1]

Who is being studied

The target population is people with type 1 diabetes mellitus who also have impaired hypoglycemic awareness and severe hypoglycemia.^[1] In simple terms, this means the trial is focused on people whose bodies do not make enough insulin and who may not notice warning signs when blood sugar becomes dangerously low.^[1] The enrollment is 44, so this is a small study group.^[1]

The source data do not provide more detailed rules for who can or cannot join, such as age limits or lab test requirements.^[1] Because of that, the clearest eligibility information available is the condition group listed in the trial record.^[1]

What the trial is measuring

The main safety checks include treatment-emergent adverse events, which are health problems that start or get worse after treatment begins.^[1] The study also tracks the incidence and severity of adverse events and serious adverse events, along with clinical laboratory values, vital signs, standard 12-lead ECGs, and imaging findings.^[1] These measurements help researchers see whether the study treatment can be given safely and how the body responds over time.^[1]

For efficacy, the key endpoint in Parts B and C is the proportion of subjects who are insulin independent at Day 365 after ZIMISLECEL infusion.^[1] Insulin independence means not needing insulin to control blood sugar, which is an important outcome for people with type 1 diabetes.^[1] The trial record says this endpoint applies to infused subjects who intended to receive 0.8 × 10E9 total SC-islet cells with one infusion.^[1]

Trial design and phase

The study is described as an interventional trial, which means the researchers assign a treatment and then watch what happens.^[1] The phase information in the source data is mixed: the title says Phase 1/2/3, while the phase field lists Phase 4.^[1] For readers, this means the record shows more than one phase label, so the trial should be understood using the exact wording in the source rather than assuming a single phase designation.^[1]

The intervention listed is “VX-880 solution for infusion,” and the study title and summary both connect the research question to ZIMISLECEL.^[1] The source data do not provide a broader explanation of the treatment beyond the trial record itself, so the article focuses only on the study purpose and outcomes.^[1]

Why this trial matters for patients

This trial is important because it focuses on people with type 1 diabetes who have a high risk of dangerous low blood sugar and may not feel warning signs early.^[1] Those patients can have serious episodes that affect daily life and safety, so researchers are looking for both safety and meaningful benefit in the trial results.^[1] The main patient-centered question is whether the study treatment can help reduce or remove the need for insulin while being safe enough to use in this group.^[1]

Because the trial record includes laboratory tests, vital signs, ECGs, and imaging, the study is not only looking at blood sugar outcomes but also at how the treatment affects the body overall.^[1] That kind of broad monitoring is common in clinical research when investigators want to understand both benefit and risk.^[1]

Table of Contents

• What is Zofenopril?
• Medical Uses
• How It Works
• Administration
• Potential Side Effects
• Precautions

What is Zofenopril?

Zofenopril calcium, also known as zofenopril hemicalcium, is a medication that belongs to a class of drugs called ACE inhibitors (Angiotensin-Converting Enzyme inhibitors)^[1]. It is primarily used to treat various cardiovascular conditions, including high blood pressure and heart failure.

Medical Uses

Zofenopril is primarily used in the treatment of:

• Heart Failure: It helps manage symptoms in patients with heart failure, particularly those with a reduced left ventricular ejection fraction (LVEF) below 50%^[1].
• Hypertension: Zofenopril is effective in lowering high blood pressure^[1].

How It Works

Zofenopril works by inhibiting the angiotensin-converting enzyme (ACE), which plays a crucial role in regulating blood pressure and fluid balance in the body. By blocking this enzyme, zofenopril helps to:

• Relax blood vessels, making it easier for the heart to pump blood
• Reduce the workload on the heart
• Lower blood pressure
• Improve blood flow throughout the body

Administration

Zofenopril calcium is typically administered orally in the form of tablets^[1]. The dosage and frequency of administration may vary depending on the patient’s condition and response to treatment. It’s important to follow your doctor’s instructions carefully when taking this medication.

Potential Side Effects

While zofenopril is generally well-tolerated, like all medications, it may cause some side effects. Common side effects may include:

• Dizziness
• Headache
• Fatigue
• Cough
• Low blood pressure

If you experience any severe or persistent side effects, it’s important to contact your healthcare provider immediately.

Precautions

Before taking zofenopril, inform your doctor if you:

• Have a history of angioedema (swelling beneath the skin)
• Are pregnant or planning to become pregnant
• Have kidney problems
• Have high levels of potassium in your blood

Your doctor will need to monitor your blood pressure and kidney function regularly while you’re taking zofenopril^[1].

Table of Contents

• Trial overview
• Who is being studied
• Study design and phase
• What the trial measures
• What the results may show

Trial overview

This clinical trial is an interventional study, which means researchers are giving a study treatment and then watching what happens.^[1] The study is titled “A Safety, Tolerability, and Efficacy Study of VX-264 in Subjects With Type 1 Diabetes.”^[1] It is currently listed as Authorised and plans to enroll 17 subjects.^[1]

Who is being studied

The target population is people with type 1 diabetes mellitus.^[1] In the trial record, the condition is listed as Type 1 Diabetes Mellitus, and the brief summary says the study is evaluating Vx-264 in subjects with T1D.^[1] The source data do not provide more detailed participation rules such as age limits or other entry requirements.^[1]

Study design and phase

The study is in Phase 1/2, which is an early research stage.^[1] Phase 1/2 studies usually focus first on safety, then begin to look for early signs that the treatment may help.^[1] The intervention listed is a VX-264 Implant given by implantation.^[1]

The trial has multiple parts, including Part A, Part B, and Part C.^[1] The source data show that Part A and Part B focus on safety and tolerability, while Part C looks at a measure of function called peak C-peptide during a mixed meal tolerance test at Day 90.^[1]

What the trial measures

The main outcomes in Parts A and B are safety and tolerability.^[1] Safety is checked by looking at treatment-emergent adverse events, serious adverse events, adverse device effects, serious adverse device events, and device deficiencies.^[1] The study also includes clinical laboratory tests, vital signs, standard 12-lead ECGs, imaging with ultrasound and magnetic resonance imaging, and retinopathy evaluation.^[1]

The trial also records how many subjects receive less than the target number of VX-264 units because of adverse events or adverse device effects.^[1] It also tracks how many subjects have VX-264 units explanted, which means removed, because of adverse events, adverse device effects, or unit integrity issues.^[1] In Part C, the main measure is the change from baseline in peak C-peptide during the mixed meal tolerance test at Day 90.^[1]

What the results may show

Based on the trial design, this study is mainly trying to learn whether Vx-264 can be used safely in people with type 1 diabetes.^[1] It is also looking for early signs of function, measured by C-peptide, which can help show whether the body is making insulin.^[1] Because this is an early-phase study with 17 subjects, it is not designed to give a final answer about long-term benefit.^[1]

Table of contents

• Trial overview
• Lung cancer studies
• Bladder cancer study
• Advanced solid tumors study
• Liver cancer study
• Cancer-associated cachexia study
• Outcomes and safety measures

Trial overview

Several interventional trials are studying VISUGROMAB in people with cancer and in people with cancer-associated cachexia.^{[1][2][3][4][5][6]}

Most of these studies are Phase 2 trials, one is a Phase 1 trial, and one is a Phase 4 trial.^{[1][2][3][4][5][6]}

The studies are authorised and use a mix of VISUGROMAB alone, VISUGROMAB with other cancer treatments, or placebo comparisons.^{[1][2][3][4][5][6]}

Lung cancer studies

Two Phase 2 trials are studying VISUGROMAB in metastatic non-squamous non-small cell lung cancer, which means lung cancer that has spread and is not the squamous type.^[1][3]

One trial is in second-line treatment, meaning it is for participants whose earlier treatment has already been used, and it compares VISUGROMAB plus nivolumab with or without docetaxel against placebo-based treatment.^[1]

The second lung cancer trial is in first-line treatment, meaning it is used at the start of treatment, and it compares VISUGROMAB plus immunochemotherapy against placebo plus the same immunochemotherapy.^[3]

Both lung cancer trials measure objective response rate, which is the share of participants whose tumors shrink enough to count as a complete or partial response.^[1][3]

Bladder cancer study

One Phase 2 study is testing VISUGROMAB in muscle invasive bladder cancer for participants who are set to undergo radical cystectomy, which is surgery to remove the bladder.^[2]

This study includes people who cannot receive cisplatin-based chemotherapy or refuse it.^[2]

The trial compares VISUGROMAB plus an anti-PD-1 checkpoint inhibitor with the anti-PD-1 treatment alone in the neoadjuvant setting, which means treatment given before surgery.^[2]

The main outcomes are pathological complete response and radiological response rate, so the study looks at both tissue findings after treatment and tumor changes on scans.^[2]

Advanced solid tumors study

One first-in-human Phase 1 study is testing CTL-002, which is named as VISUGROMAB in the trial data, in people with advanced-stage, relapsed/refractory solid tumors.^[4]

“First-in-human” means this is the first time the treatment was tested in people in this study program.^[4]

The study includes participants with bladder cancer, hepatocellular cancer, non-small cell lung cancer, melanoma, colorectal cancer with microsatellite stable or mismatch-repair competent disease, and a mixed “basket” cohort of solid tumors.^[4]

The trial looks at early anti-tumor activity and also checks safety and tolerability using side effects, lab tests, vital signs, ECGs, physical exams, neurological checks, and ECOG performance status.^[4]

Liver cancer study

One Phase 2 trial is studying VISUGROMAB in unresectable or metastatic hepatocellular carcinoma, which is liver cancer that cannot be removed with surgery or has spread.^[5]

This study includes participants with compensated liver function, called Child-Pugh A, which means the liver is still working well enough for this classification.^[5]

The trial compares VISUGROMAB plus nivolumab and lenvatinib against double placebo and lenvatinib in people who had already failed anti-PD-(L)1 treatment.^[5]

The primary outcome is progression-free survival, which measures how long people live without the cancer getting worse or death occurring first.^[5]

Cancer-associated cachexia study

One Phase 4 study is testing VISUGROMAB in cancer-associated cachexia, a condition linked to cancer that causes weight loss and poor appetite.^[6]

This trial compares VISUGROMAB with placebo matching VISUGROMAB and includes a large planned enrollment of 626 participants.^[6]

The main outcomes are change in body weight and change in appetite after 12 weeks, using the 5-item anorexia subscale of the FAACT tool for appetite measurement.^[6]

Outcomes and safety measures

The lung cancer and bladder cancer trials focus on tumor response, including complete response, partial response, and radiological response on scans.^[1][2][3]

The liver cancer trial focuses on progression-free survival, while the cachexia study focuses on body weight and appetite changes.^[5][6]

The Phase 1 trial also records safety data such as adverse events, laboratory results, vital signs, ECG findings, physical exam results, and performance status.^[4]

Across these studies, VISUGROMAB is being tested in different patient groups, so the main goal is to learn where it may help most and how it performs in each setting.^{[1][2][3][4][5][6]}

Table of Contents

• Trial overview
• Impaired renal function and suspected MASH
• Alport syndrome study
• What was measured in the studies
• Who the studies focused on

Trial overview

Two Phase 2 ^[1][2] interventional studies were listed for Vonafexor, and both were marked completed.^[1][2] These studies looked at different patient groups: one with impaired renal function and suspected MASH, and one with Alport syndrome at risk of progression.^[1][2]

Impaired renal function and suspected MASH

The study with NCT ID 2023-509192-16-00 enrolled 50 people and was completed.^[1] It studied people with impaired renal function and suspected MASH, which means a liver condition with fat and inflammation, along with reduced kidney function.^[1] The brief summary said the goal was to determine the effect of Vonafexor on renal function in people with suspected MASH and mild to moderately reduced GFR.^[1]

The primary outcome was the change from baseline in mGFRiohexol and eGFRcreat at week 16.^[1] In simple terms, the study checked whether kidney filtering changed after treatment compared with the start of the study.^[1] The listed interventions included Vonafexor by mouth at 25 mg and 100 mg, along with rosuvastatin and iohexol used for measurement.^[1]

Alport syndrome study

The study with NCT ID 2023-509638-20-00 enrolled 24 patients and was also completed.^[2] It focused on patients with Alport syndrome who were at risk of progression.^[2] The brief summary said the purpose was to assess the safety and tolerability of Vonafexor both during treatment and after treatment stopped.^[2]

The primary outcome tracked the number of treatment-emergent adverse events from the first dose until 2 weeks after the last dose.^[2] It also measured changes in physical examinations, vital signs, laboratory variables, and lipid profile compared with baseline, which is the starting point before treatment begins.^[2] The intervention listed for this study was oral Vonafexor 100 mg.^[2]

What was measured in the studies

The kidney-focused study measured GFR, which is a way to see how well the kidneys filter blood.^[1] It used both a measured method with iohexol and an estimated method based on creatinine.^[1] The Alport syndrome study focused more on safety checks, including adverse events, physical exams, vital signs, laboratory values, and blood fats.^[2]

• Baseline means the starting point before treatment or study procedures begin.^[2]
• Vital signs are basic body measurements such as blood pressure and pulse.^[2]
• Laboratory variables are blood or urine test results that help show how the body is working.^[2]
• Lipid profile is a blood test that measures fats such as cholesterol.^[2]

Who the studies focused on

These trials were not broad studies of all patients with kidney or liver disease.^[1][2] They focused on specific groups: people with suspected MASH and reduced kidney function, and people with Alport syndrome at risk of getting worse.^[1][2] This makes the results more relevant to those exact patient groups, but not necessarily to everyone with similar symptoms.^[1][2]

Table of Contents

• Clinical trial overview
• Kidney transplant study
• Type 2 diabetes studies
• Other trial use
• Main endpoints and what they mean
• Who the studies are for

Clinical trial overview

The trial data show that Vildagliptin is being studied in interventional clinical trials, which means researchers give a treatment and measure the results.^[1] The listed studies are in Phase 2 and Phase 3, which are stages used to test how well a treatment works in people and to collect more safety and outcome data.^[1][2]

Kidney transplant study

The PRODIG study, NCT02849899, is a Phase 3 trial in people after renal transplant, which means kidney transplant.^[1] It is authorised and plans to enroll 186 participants.^[1]

This study is testing whether a short-term course of Vildagliptin in the early post-transplant period can prevent new onset diabetes after transplantation, meaning diabetes that starts after the transplant.^[1] The main result is the proportion of patients who have diabetes 1 year after transplantation, based on diabetes treatment use, fasting glucose above 7 mmol/L, or an abnormal oral glucose tolerance test (OGTT).^[1]

Type 2 diabetes studies

One authorised Phase 3 study, 2025-520686-46-00, is in adults with Type 2 Diabetes Mellitus and plans to enroll 504 participants.^[2] It is studying whether treatment guided by genetics, called pharmacogenetic-guided treatment, works better than optimized standard treatment for people whose diabetes is not well controlled.^[2]

In this study, Vildagliptin appears among the treatment options used in the trial plan.^[2] The main endpoint is the proportion of patients who reach HbA1c ≤7% at Week 24 in the experimental arm compared with the control arm.^[2]

Another large Phase 3 study, NCT05433584, is also in adults with Type 2 Diabetes and has an enrollment of 781 participants.^[4] Vildagliptin is listed among many treatment options in this study, which compares tirzepatide with intensified conventional care.^[4] The main endpoint is change from baseline in HbA1c, a blood test that shows average blood sugar over time.^[4]

Other trial use

A completed Phase 2 study, 2024-511295-33-00, looked at people with advanced breast cancer treated with alpelisib plus endocrine therapy.^[3] Vildagliptin was listed among the trial treatments, along with other medicines used in the study.^[3]

This trial focused on hyperglycemia, which means high blood sugar, during the first 8 weeks of alpelisib treatment.^[3] One main endpoint was the rate of grade 3-4 hyperglycemia in cohorts A and B, and another was permanent discontinuation of alpelisib due to related adverse events in cohort C.^[3]

Main endpoints and what they mean

Clinical trials use endpoints, which are the main results they want to measure.^[1][2][3][4]

• Diabetes prevention after transplant: the study checks how many patients have diabetes 1 year after kidney transplantation.^[1]

• HbA1c target: the study checks how many people reach HbA1c ≤7% at Week 24.^[2]

• Change in HbA1c: the study measures how blood sugar control changes from the start of the study to later time points.^[4]

• Hyperglycemia during cancer treatment: the study measures how often severe high blood sugar happens in the first 8 weeks.^[3]

Who the studies are for

The trial data show that Vildagliptin is being studied in different patient groups, not just one disease area.^[1][2][3][4]

• People after kidney transplant, where the study asks if early treatment can lower later diabetes risk.^[1]

• Adults with type 2 diabetes, where the study looks at better blood sugar control with tailored treatment.^[2]

• People in a cancer treatment setting, where the study examined blood sugar problems during alpelisib therapy.^[3]

Table of Contents

• Clinical trials overview
• Type 1 diabetes studies
• Heart disease and rhythm studies
• Other pediatric study
• Outcomes and endpoints
• Study designs and participants

Clinical trials overview

The trials in this set study Verapamil in several different patient groups, including people with type 1 diabetes, hypertrophic cardiomyopathy, ventricular fibrillation, frequent premature ventricular complexes, and tuberous sclerosis complex.^{[1][2][3][4][5]}

Across these studies, Verapamil is being tested in different ways: alone, compared with placebo, and compared with other active drugs.^{[1][2][3][4][5]}

Type 1 diabetes studies

One Phase 2 study, Image-VER-A-T1D, includes adults with type 1 diabetes and has 30 planned participants.^[1] It compares treatment with Verapamil and EXENATIDE against a placebo group, and the main goal is to measure pancreatic uptake on PET/CT as a way to estimate beta cell mass before and after treatment.^[1]

Another study is a Phase 1 trial in children with recent-onset type 1 diabetes, with 36 planned participants.^[3] This double-blind, randomized, placebo-controlled study looks at whether oral Verapamil can help preserve residual insulin secretion, which means the amount of insulin the body still makes after diagnosis.^[3]

The main safety endpoint in part A is the frequency of adverse events and serious adverse events during treatment, while part B measures change in C-peptide during a mixed meal tolerance test at month 24.^[3]

Heart disease and rhythm studies

One Phase 3 study in 140 patients examines Verapamil in symptomatic people with non-obstructive hypertrophic cardiomyopathy.^[2] The study aims to reduce symptoms and arrhythmic complications, and it measures changes in VO2 max, left ventricular end-diastolic volume, and the incidence of non-sustained ventricular tachycardia.^[2]

Another Phase 2 pilot trial compares Verapamil with QUINIDINE in short-coupled idiopathic ventricular fibrillation.^[4] This open-label, randomized crossover study has 24 planned participants and looks at sustained ventricular arrhythmia using a severity scoring system.^[4]

A larger low-intervention study called SUPPRESS includes asymptomatic patients with frequent PVCs and normal LVEF, with 298 planned participants.^[5] It tests whether preventive treatment, including Verapamil and other drugs, can lower the risk of later left ventricular dysfunction within 2 years.^[5]

Other pediatric study

One Phase 2 study in 64 children under 4 months of age with tuberous sclerosis complex includes Verapamil among several treatment options.^[6] The study compares treatment strategies with standard of care alone and measures neuropsychologic outcome at 24 months using Bayley Scales of Infant and Toddler Development III testing.^[6]

Outcomes and endpoints

The main endpoints differ by disease area, but they all focus on measurable signs of benefit or harm.^{[1][2][3][4][5][6]}

• In diabetes studies, the main outcomes look at pancreatic imaging, beta cell mass, and C-peptide, which help show how much insulin-making function remains.^[1][3]

• In heart studies, the outcomes include exercise capacity, heart chamber size, arrhythmia events, and left ventricular function, which show how well the heart is working.^[2][4][5]

• In the pediatric neurodevelopment study, the outcome is cognitive testing at 24 months, which checks early brain development and learning skills.^[6]

Study designs and participants

The studies use several common research designs, including interventional trials, randomized trials, placebo-controlled trials, and crossover studies.^[1][3][4]

Participants vary by trial: some studies enroll adults, some enroll children, and some focus on people with no symptoms but a specific heart rhythm finding.^[1][3][5][6]

Trial phases also vary, from Phase 1 safety and early testing to Phase 3 larger confirmatory research, showing that Verapamil is being studied at different stages of development for different conditions.^[2][3][4]

Table of contents

• Clinical trials overview
• Heart failure and related heart studies
• Marfan syndrome and aortic disease
• Kidney transplant study
• Healthy volunteer bioequivalence studies
• Main endpoints used in the trials
• Who can participate

Clinical trials overview

The trial data shows that Valsartan is being studied in a wide range of clinical settings, mostly in heart disease and blood vessel disease. These studies include both direct Valsartan trials and trials where Valsartan is part of a combination treatment such as sacubitril/valsartan.^[1][2]

The studies are in different stages, including Phase 1, Phase 2, and Phase 3, plus some low-intervention trials. This means the research ranges from early testing in healthy volunteers to larger patient studies that measure real health outcomes.^[3][4]

Heart failure and related heart studies

Most of the listed trials focus on heart failure, which is when the heart does not pump blood as well as it should. Several studies look at whether Valsartan, alone or in combination, can help prevent worsening heart function or reduce later heart failure events.^[5][6]

One authorised Phase 3 study in people with diabetes mellitus type 2 is testing whether high-dose treatment with RAS-antagonists and beta-blockers can reduce cardiac death or cardiac hospitalisation. Valsartan 320 mg is one of the study drugs, and the trial uses a combined endpoint based on the first cardiac death or cardiac hospitalisation.^[7]

Another Phase 2 heart failure study is testing XXB750 in symptomatic patients with LVEF below 50%, while patients receive standard care that may include ACE inhibitors, ARBs, or sacubitril/valsartan. The main outcome is the change in log NT-proBNP from baseline to Week 16.^[8]

A Phase 3 study in ischemic heart failure with mid-range ejection fraction compares sacubitril/valsartan with ramipril and measures the change in left ventricular end-systolic volume after 12 months by MRI. This helps researchers see whether treatment changes heart size and shape over time.^[9]

Another authorised Phase 3 study looks at pharmacological optimisation in heart failure and includes Valsartan among many treatment options. It has both a retrospective part, which studies current prescribing patterns and sex differences, and a prospective part, which measures mortality, heart failure readmission, quality of life, adherence, and side effects.^[10]

Several other heart failure trials study withdrawal, continuation, or timing of treatment in patients who improved after cardiac resynchronisation therapy or who have recovered left ventricular function. In these studies, Valsartan appears in the treatment lists, and the main concern is whether stopping or changing therapy leads to relapse of cardiomyopathy or heart failure.^[11][12]

One completed Phase 3 trial compared sacubitril/valsartan with enalapril in patients with heart failure with reduced ejection fraction and pulmonary hypertension. The main outcomes were changes in mean pulmonary artery pressure and pulmonary vascular resistance, which are measures of pressure and resistance in the lung circulation.^[13]

Another completed Phase 3 trial in heart failure with preserved ejection fraction and secondary mitral valve regurgitation studied sacubitril/valsartan and measured the slope of mPAP/CO during exercise testing. Secondary outcomes included valve measurements and quality of life.^[14]

There is also an authorised Phase 3 trial in heart failure with recovered ejection fraction that studies whether stopping beta-blockers is non-inferior to continuing them. Valsartan appears in the intervention list, and the primary endpoint is a composite of heart failure relapse and other adverse cardiovascular outcomes during follow-up.^[15]

Marfan syndrome and aortic disease

One authorised Phase 3 trial studies Marfan syndrome and related inherited aortic diseases in children and young adults. The goal is to see whether Valsartan can slow the widening of the aortic root, which is the first part of the aorta coming out of the heart.^[16]

The primary outcome in this study is the annual change in aortic diameter measured by transthoracic echocardiography, which is an ultrasound scan of the heart. This is a direct way to track whether the aorta grows more slowly over time.^[16]

Another Phase 3 trial in arrhythmogenic cardiomyopathy studies sacubitril/valsartan and looks at left ventricular fibrosis, left ventricular ejection fraction, and ventricular arrhythmia burden. Although this study uses the combination treatment, it still belongs to the wider group of Valsartan-related trials in the dataset.^[17]

Kidney transplant study

One authorised Phase 3 study is in renal transplant patients with signs of post-transplant glomerulopathy. It tests whether Valsartan can help prevent a drop in glomerular filtration, which is a measure of kidney filtering function.^[18]

This trial does not list a primary endpoint in the source data, but its brief summary makes the research aim clear: to see whether an ARB can help protect kidney function in a specific transplant subgroup with urinary PECs.^[18]

Healthy volunteer bioequivalence studies

Two completed Phase 1 studies enrolled healthy volunteers to compare two formulations of sacubitril/valsartan. These studies were designed to show bioequivalence, meaning the test product and reference product behave similarly in the body.^[19][20]

The main outcomes were sacubitril and Valsartan blood exposure measures, including AUC0-t and Cmax. These measures help researchers compare how much medicine gets into the blood and how high the blood level becomes after dosing.^[19][20]

Main endpoints used in the trials

The trials use many different endpoints, but several are repeated across studies. Common heart outcomes include changes in left ventricular ejection fraction, left ventricular volume, heart failure relapse, and hospitalisation for heart failure or cardiac causes.^[5][9][11]

Some studies focus on blood markers such as NT-proBNP, which can reflect how much strain is placed on the heart. Others use imaging tests like MRI, echocardiography, or stress testing to measure heart structure and function more directly.^[8][14]

In the Marfan study, the main endpoint is the yearly change in aortic diameter. In the kidney transplant study, the goal is to protect glomerular filtration. In the bioequivalence studies, the main endpoints are AUC and Cmax for sacubitril and Valsartan.^[16][18][19]

Who can participate

Participation depends on the study question. The trials include healthy volunteers, adults with heart failure, people with diabetes and no known heart disease, patients with cardiomyopathy, children and young adults with Marfan-related disease, and kidney transplant recipients.^{[1][7][16][18]}

Some studies are looking for people with recovered heart function, while others focus on patients with active symptoms or special heart conditions such as pulmonary hypertension or mitral valve regurgitation. This shows that Valsartan-related research is aimed at very different patient groups, not just one disease.^[11][13][14]

Table of Contents

• Trial overview
• Conditions and patient groups
• Trial phases and study designs
• Main endpoints and what they mean
• Selected trial details
• Patient glossary

Trial overview

Clinical trials with Vancomycin Hydrochloride are looking at several different clinical questions, not only one disease area.^[1][2] The studies include prevention of surgical site infection, treatment of Clostridioides difficile infection, use in serious infections, and research in bowel disease and cancer.^[1][2]

The trials are mostly interventional, which means the researchers assign a treatment and then measure the results.^[1][2] The listed studies are in Phase 2 or Phase 3, showing that they are testing treatment effects in patients and comparing options in larger or more focused groups.^[1][2]

Conditions and patient groups

One Phase 3 study is testing surgical antibiotic prophylaxis, which means antibiotic treatment given around surgery to help prevent infection.^[1] This study includes patients having surgery, and it compares linezolid with vancomycin for prevention of surgical site infection.^[1]

Several trials focus on infection-related conditions. These include Staphylococcus aureus bacteremia, staphylococcal endocarditis, serious infections needing intravenous treatment, and Clostridioides difficile infection.^[3][4][6][7] Some of these studies are for adults with severe illness, while others are for children with infection disease or inflammatory bowel disease.^[3][9][10]

There are also studies in ulcerative colitis, including a Phase 2 study in mild-to-moderate disease and a pediatric study that looks at bowel healing and stool markers.^[2][10] In cancer research, Vancomycin Hydrochloride appears in studies of hepatocellular carcinoma, which is a type of liver cancer.^[5][8]

Trial phases and study designs

The trial list includes Phase 2 and Phase 3 studies only.^[1][2] Phase 2 studies in this set include ulcerative colitis, Clostridioides difficile infection, hepatocellular carcinoma, and pediatric inflammatory bowel disease.^{[2][5][7][8][10]}

Phase 3 studies include surgical infection prevention, serious infections with model-informed dosing, staphylococcal endocarditis, pediatric infection treatment by continuous infusion, and diabetic foot osteomyelitis.^{[1][3][4][6][9][11]}

Some studies compare one treatment with another, such as linezolid versus vancomycin, or a shorter versus longer course of oral vancomycin.^[1][7] Other studies compare active treatment with placebo, which is an inactive look-alike treatment used for fair comparison.^[2][8]

Main endpoints and what they mean

A primary outcome is the main result a trial is designed to measure.^[1] In these studies, the main outcomes include surgical site infection rates by day 30, endoscopic response by day 56, and recurrence of Clostridioides difficile infection within 60 days after treatment ends.^[1][2][7]

Some trials look at survival and treatment failure. For example, one study measures 90-day survival without clinical or microbiological failure, and another measures 6-month all-cause mortality after randomization.^[4][6] These outcomes help show whether a treatment keeps patients alive and whether the infection comes back or does not improve.

Other studies focus on safety and biological response. Safety outcomes include treatment-emergent adverse events, serious adverse events, and events rated as severe.^[2][5][8] Cancer and bowel disease studies also measure immune or tissue changes, such as CD8+ T cells in tumor tissue or stool calprotectin, which is a marker of bowel inflammation.^[8][10]

The ProVanc study measures whether patients stay in the therapeutic target range, meaning the planned treatment exposure range, for most of the treatment time.^[3] The pediatric continuous infusion study measures hospital stay, fever duration, readmission, and possible relapse.^[9] The diabetic foot osteomyelitis study measures whether the ulcer or bone infection is healed at 12 and 24 weeks.^[11]

Selected trial details

• LOVip is a Phase 3 study in surgical antibiotic prophylaxis with 1,160 planned participants. It compares linezolid with vancomycin and measures surgical site infection rates at 30 days after surgery.^[1]

• NCT05370885 is a Phase 2 study in mild-to-moderate ulcerative colitis with 172 participants. It measures endoscopic response at day 56 and tracks safety in both blinded and open-label parts.^[2]

• ProVanc is a Phase 3 study in critically ill adults with serious infections needing intravenous vancomycin. It tests a model-informed precision dosing tool and measures how often patients stay in the target exposure range.^[3]

• SAB 7 is a Phase 3 study in uncomplicated Staphylococcus aureus bacteremia with 284 participants. It compares 7 days versus 14 days of antibiotic therapy and measures 90-day survival without treatment failure or relapse.^[4]

• RESCUE-HUB is a Phase 2 study in unresectable hepatocellular carcinoma with 15 participants. It looks at safety and disease control after fecal microbiota transplantation added to first-line therapy, and Vancomycin Hydrochloride is part of the intervention list.^[5]

• RIFREE is a Phase 3 study in staphylococcal prosthetic valve endocarditis with 422 participants. It measures all-cause mortality at 6 months after randomization and includes a vancomycin-containing regimen among the study treatments.^[6]

• ANTROP-I is a Phase 2 study in Clostridioides difficile infection with 244 participants. It compares 5-day treatment with the standard 10-day oral vancomycin course and measures recurrence within 60 days after treatment ends.^[7]

• FLORA is a Phase 2 study in hepatocellular carcinoma with 48 participants. It measures tumor CD8+ T lymphocytes after two cycles of treatment and tracks safety events through day 105.^[8]

• Continuous antibiotic infusion in children is a Phase 3 study with 150 planned participants. It includes Vancosan and measures hospital stay, fever, antibiotic treatment duration, readmission, and relapse.^[9]

• Oral vancomycin therapy in pediatric inflammatory bowel disease is a Phase 2 study with 140 participants. It measures remission and stool inflammation markers, and it compares findings before and after treatment.^[10]

• LIBRETTO is a Phase 3 study in diabetic foot osteomyelitis with 84 participants. It compares local antibiotic delivery with systemic antibiotic therapy and measures healing and resolution at 12 and 24 weeks.^[11]

Patient glossary

Surgical site infection means an infection that happens in the area of the body where surgery was done.^[1]

Bacteremia means bacteria are present in the blood.^[4]

Endocarditis is an infection of the inner lining or valves of the heart.^[6]

Flexible sigmoidoscopy is a test that uses a small camera to look inside the lower bowel.^[2]

Mayo endoscopic subscore is a score used to rate how inflamed the bowel looks during the camera test.^[2]

RECIST 1.1 is a way to measure whether a cancer is shrinking, stable, or growing.^[5]

CD8+ T lymphocytes are immune cells that can be counted in tissue samples to study the immune response.^[8]

Calprotectin is a stool marker that can show bowel inflammation.^[10]

Osteomyelitis means infection of the bone.^[11]

Placebo is a look-alike treatment with no active medicine, used to compare results fairly.^[2][8]

Table of Contents

• What is VANGLUSAGENE ENSIPARVOVEC?
• Target Condition: Late-Onset Pompe Disease
• How VANGLUSAGENE ENSIPARVOVEC Works
• Current Clinical Trial
• Eligibility Criteria
• Safety and Efficacy Evaluation
• Potential Benefits

What is VANGLUSAGENE ENSIPARVOVEC?

VANGLUSAGENE ENSIPARVOVEC, also known as SPK-3006, is an innovative gene therapy being developed to treat Late-Onset Pompe Disease (LOPD)^[1]. It is classified as an orphan drug, which means it is intended to treat a rare disease^[2]. This therapy is currently undergoing clinical trials to evaluate its safety and effectiveness in patients with LOPD.

VANGLUSAGENE ENSIPARVOVEC is a recombinant adeno-associated viral vector that contains a specially designed genetic material. This genetic material is intended to produce a secretable form of human acid alpha-glucosidase (GAA), an enzyme that is deficient in people with Pompe disease^[3].

Target Condition: Late-Onset Pompe Disease

VANGLUSAGENE ENSIPARVOVEC is designed to treat Late-Onset Pompe Disease (LOPD), also known as glycogen storage disease type II^[4]. Pompe disease is a rare genetic disorder characterized by the buildup of a complex sugar called glycogen in the body’s cells. This accumulation affects various body tissues and organs, particularly the muscles, leading to progressive muscle weakness.

In LOPD, symptoms typically appear later in childhood, adolescence, or adulthood. These may include:

• Progressive muscle weakness, especially in the legs and trunk
• Breathing problems, particularly when lying down
• Fatigue
• Difficulty walking or climbing stairs

How VANGLUSAGENE ENSIPARVOVEC Works

VANGLUSAGENE ENSIPARVOVEC is a gene therapy that aims to address the underlying cause of Pompe disease. Here’s how it works:

1. The therapy uses a modified virus (adeno-associated virus) as a vehicle to deliver a functional copy of the GAA gene to the patient’s cells.
2. This gene contains instructions for producing the GAA enzyme, which is lacking in people with Pompe disease.
3. Once inside the cells, the gene should lead to the production of functional GAA enzyme.
4. The therapy is designed to produce a secretable form of GAA, which means the enzyme can be released from cells and potentially taken up by other cells in the body.

By increasing the levels of functional GAA enzyme in the body, VANGLUSAGENE ENSIPARVOVEC aims to reduce the accumulation of glycogen in cells and alleviate the symptoms of Pompe disease^[5].

Current Clinical Trial

VANGLUSAGENE ENSIPARVOVEC is currently being studied in a Phase 1/2 clinical trial. This trial is designed to evaluate the safety, tolerability, and potential efficacy of a single intravenous infusion of the therapy in adults with late-onset Pompe disease^[6].

Key aspects of the trial include:

• It is a dose-escalation study, meaning different dose levels will be tested to find the optimal dose.
• The therapy is administered as a single intravenous infusion.
• Participants will be adults (18 years and older) with confirmed LOPD.
• The study aims to include patients with moderately advanced disease who can still walk at least 75 meters but less than 500 meters in a 6-minute walk test.

Eligibility Criteria

To participate in the clinical trial, patients must meet specific criteria. Some key eligibility factors include^[7]:

• Confirmed diagnosis of LOPD
• Age 18 years or older
• Have been receiving enzyme replacement therapy (ERT) for at least 24 months
• Able to walk between 75 and 500 meters in a 6-minute walk test
• Have a forced vital capacity (a measure of lung function) between 30% and 80% of predicted value

There are also several exclusion criteria, such as prior gene therapy treatment, active infections, significant liver disease, and others. It’s important to note that eligibility is determined by healthcare professionals based on a comprehensive evaluation^[8].

Safety and Efficacy Evaluation

The primary focus of the current clinical trial is to assess the safety and tolerability of VANGLUSAGENE ENSIPARVOVEC. Researchers will be monitoring^[9]:

• Adverse events and serious adverse events
• Changes in laboratory values, vital signs, and physical examinations
• Immune responses against the therapy
• Liver function tests

To evaluate the potential efficacy of the treatment, the study will measure^[10]:

• Changes in the distance walked in the 6-minute walk test
• Changes in forced vital capacity (a measure of lung function)
• Levels of GAA enzyme in the blood
• Biomarkers of muscle injury and glycogen accumulation

Potential Benefits

While it’s important to note that VANGLUSAGENE ENSIPARVOVEC is still in the experimental stage, it has the potential to offer several benefits for people with LOPD^[11]:

• Long-lasting treatment: As a gene therapy, it may provide a long-term solution with a single treatment, unlike current enzyme replacement therapies that require regular infusions.
• Improved muscle function: By addressing the underlying cause of the disease, it may help improve muscle strength and function.
• Enhanced quality of life: If successful, it could significantly improve the daily lives of people with LOPD by reducing symptoms and slowing disease progression.
• Reduced treatment burden: A one-time treatment could eliminate the need for frequent hospital visits for enzyme replacement therapy.

It’s crucial to remember that these potential benefits are still being investigated in clinical trials, and more research is needed to confirm the safety and efficacy of VANGLUSAGENE ENSIPARVOVEC^[12].